Gordon Dunn Biography and Net Worth

Gordon joined Quoin in November of 2021. He brings over 30 years of finance experience and has served as CFO of both private and publicly traded companies. In addition, Mr. Dunn has deep experience in investment banking and private equity. Over the last five years he has served as Chief Financial Officer for several private companies, most recently with Qured, a UK based healthcare provider, from 2020 to 2021. Mr Dunn also served as CFO of Innocoll Inc. from 2012-2016. Prior to joining Innocoll, Mr. Dunn had 20 years’ experience in investment banking and private equity, including over ten years managing the private equity funds of NewSmith Capital, and nine years at Merrill Lynch where he served as co-head of the European Private Equity Group and Director of Equity Capital Markets. Mr. Dunn received a B.A. from Stanford University and a J.D. from New York University School of Law.

What is Gordon Dunn's net worth?: The estimated net worth of Gordon Dunn is at least $20.37 thousand as of December 23rd, 2024. Mr. Dunn owns 4,316 shares of Quoin Pharmaceuticals stock worth more than $20,372 as of October 7th. This net worth approximation does not reflect any other investments that Mr. Dunn may own. Learn More about Gordon Dunn's net worth.
How do I contact Gordon Dunn?: The corporate mailing address for Mr. Dunn and other Quoin Pharmaceuticals executives is 23 Hata'as Street, Kfar Saba, 44425. Quoin Pharmaceuticals can also be reached via phone at +97299741444 and via email at [email protected]. Learn More on Gordon Dunn's contact information.
Has Gordon Dunn been buying or selling shares of Quoin Pharmaceuticals?: Gordon Dunn has not been actively trading shares of Quoin Pharmaceuticals during the last quarter. Most recently, on Monday, December 23rd, Gordon Dunn bought 3,492 shares of Quoin Pharmaceuticals stock. The stock was acquired at an average cost of $15.75 per share, with a total value of $54,999.00. Following the completion of the transaction, the chief financial officer now directly owns 4,316 shares of the company's stock, valued at $67,977. Learn More on Gordon Dunn's trading history.
Who are Quoin Pharmaceuticals' active insiders?: Quoin Pharmaceuticals' insider roster includes Denise Carter (COO), Anthony Culverwell (Director), Gordon Dunn (CFO), and Dennis Langer (Director). Learn More on Quoin Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Quoin Pharmaceuticals?: In the last twelve months, Quoin Pharmaceuticals insiders bought shares 5 times. They purchased a total of 72,522 shares worth more than $408,606.08. The most recent insider tranaction occured on August, 31st when COO Denise P. Carter bought 20,490 shares worth more than $99,991.20. Insiders at Quoin Pharmaceuticals own 11.2% of the company. Learn More about insider trades at Quoin Pharmaceuticals.
Information on this page was last updated on 8/31/2026.

Gordon Dunn Insider Trading History at Quoin Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/23/2024	Buy	3,492	$15.75	$54,999.00	4,316
9/9/2024	Buy	253	$27.65	$6,995.45	253

Gordon Dunn Buying and Selling Activity at Quoin Pharmaceuticals

Quoin Pharmaceuticals Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Today's Range

Now: $4.62

$4.51

$4.79

50 Day Range

MA: $5.73

$4.26

$7.87

2 Week Range

Now: $4.62

$3.25

$41.80

Volume

3,610 shs

Average Volume

292,420 shs

Market Capitalization

$9.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56